Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Study Details
- Hemophilia
- Drug: Marstacimab
- \- Participants with a diagnosis of hemophilia A or hemophilia B eligible to receive prophylaxis.
- Clinical physicians prescribe marstacimab for routine prophylaxis treatment of hemophilia patients based on the actual conditions of the patients and in accordance with the approved indications of marstacimab.
- Adolescent patients(12 to less than 18 years) and adult (18 years and older) patients.
- Signed consent obtained before the study, participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent.
- \- Those who are unable to complete at least one month follow-up based on the investigator's judgment.
- Severe impairment of speech, vision, memory or cognition that affects communication and ability to complete questionnaires and follow-up visits.
- Women of childbearing age who plan to become pregnant within the next 2 months, as well as women who are pregnant or breastfeeding.
- Patients are participating in other clinical trials. There are other conditions that the investigator deems unsuitable for participation in this study.
Protocol Summary
This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.